{"id":"W2922202278","doi":"10.1200/jco.2019.37.7_suppl.546","title":"First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Renal cell carcinoma; Internal medicine; Chromophobe cell; Clinical endpoint; Population; Surgery; Oncology; Gastroenterology; Clear cell; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001747234,0.0007796751,0.0008038262,0.0004712018,0.0004919596,0.0007591593,0.0005919163,0.0007457589,0.003245354],"category_scores_gemma":[0.0009704378,0.0002889164,0.0009660688,0.0004228429,0.0002580846,0.0005013038,0.0004724929,0.0009497681,0.001011636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009346597,"about_ca_system_score_gemma":0.001707708,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005441801,"about_ca_topic_score_gemma":0.007449835,"domain_scores_codex":[0.9994813,0.0001899082,0.00004043271,0.00009785541,0.00009012369,0.0001004935],"domain_scores_gemma":[0.9986169,0.0001795322,0.0002277318,0.0001785103,0.0002178631,0.0005794029],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5633085,0.04396192,0.198392,0.001580464,0.005826815,0.00103334,0.000674765,0.003489768,0.034265,0.0003595075,0.050834,0.09627385],"study_design_scores_gemma":[0.2125648,0.2241441,0.5167059,0.000321653,0.003670061,0.001982206,0.0005586477,0.002409882,0.009350393,0.000379772,0.0277779,0.0001345958],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9750806,0.001532186,0.0003171565,0.000231123,0.00004754284,0.001439153,0.01877953,0.00004960278,0.002523089],"genre_scores_gemma":[0.9105632,0.001576036,0.001312441,0.0009041605,0.0001407667,0.001571303,0.08010858,0.00004787054,0.003775646],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005441801,"threshold_uncertainty_score":0.01085681,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0593579845230985,"score_gpt":0.3813226172702995,"score_spread":0.3219646327472011,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}